Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $41.40.

Several equities research analysts recently commented on COAG shares. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Wedbush assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $42.00 price target for the company.

Insider Activity

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the transaction, the insider owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders bought 2,970,541 shares of company stock worth $55,459,603.

Hemab Therapeutics Stock Up 13.5%

NASDAQ COAG opened at $36.73 on Tuesday. Hemab Therapeutics has a one year low of $23.00 and a one year high of $38.87. The stock has a 50-day simple moving average of $27.41.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.